ALPK2 is Crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2301-2308

  Yoshida, Yasuhiro ^a   Tsunoda, Toshiyuki ^a   Doi, Keiko ^a   Fujimoto, Takahiro ^a   Tanaka, Yoko ^a   Ota, Takeharu ^a   Ogawa, Masahiro ^a   Matsuzaki, Hiroshi ^a   Kuroki, Masahide ^a   Iwasaki, Akinori ^a   Shirasawa, Senji ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

ALPK2; Apoptosis; Colorectal cancer; DNA repair related genes; Three dimensional culture

Indexed keywords

ALPHA KINASE 2; ALPHA KINASE 2 ANTIBODY; ANTIBODY; CASPASE 3; ENZYME; K RAS PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ALPK2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHOTRANSFERASE; PROTEIN KINASE; RAS PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; COLON; COLORECTAL ADENOMA; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; CELL STRAIN HCT116; CELL TRANSFORMATION; COLORECTAL TUMOR; CONFOCAL MICROSCOPY; DNA MICROARRAY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOTRANSFERASES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84864537175     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Rosin-Arbesfeld R, Ihrke G and Bienz M: Actin-dependent membrane association of the APC tumour suppressor in polarized mammalian epithelial cells. EMBO J 20: 5929-5939, 2001.
3. Cho KR and Vogelstein B: Genetic alterations in the adenoma-carcinoma sequence. Cancer 70: 1727-1731, 1992.
4. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10 : 789-799, 2004.
5. Shirasawa S, Furuse M, Yokoyama N and Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-RAS. Science 260 : 85-88, 1993.
6. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N and Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105: 1734-1741, 2005.
7. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A, Song X, Ulrich CM, Sasazuki T, Shirasawa S and Grady WM: TGF-β receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a β-catenin-independent pathway. Gastroenterology 136 : 1680-1688, 2009.
8. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51, 2010.
9. Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T and Shirasawa S: Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia 12 : 397-404, 2010.
10. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S and Bardelli A: De-regulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866, 2010.
11. Ryazanov AG, Pavur KS and Dorovkov MV: Alpha-kinases: a new class of protein kinases with a novel catalytic domain. Curr Biol 9: R43-45, 1999.
12. Johnson-Pais TL, Nellissery MJ, Ammerman DG, Pathmanathan D, Bhatia P, Buller CL, Leach RJ and Hansen MF: Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. Int J Cancer 105: 285-288, 2003.
13. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal tumor development. N Engl J Med 319 : 525-532, 1988.
14. Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER and Cho KR: Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 10: 1362-1372, following 1372, 2008.
15. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA and Stratton MR: Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158, 2007.
16. Fujimoto T, Koyanagi M, Baba I, Nakabayashi K, Kato N, Sasazuki T and Shirasawa S: Analysis of KRAP expression and localization, and genes regulated by KRAP in a human colon cancer cell line. J Hum Genet 52: 978-984, 2007.
17. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E and Sasazuki T: Involvement of de-regulated epiregulin expression in tumorigenesis in vivo through activated Ki-RAS signaling pathway in human colon cancer cells. Cancer Res 60: 6886-6889, 2000.
18. Debnath J, Muthuswamy SK and Brugge JS: Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268, 2003.
19. Koyanagi M, Nakabayashi K, Fujimoto T, Gu N, Baba I, Takashima Y, Doi K, Harada H, Kato N, Sasazuki T and Shirasawa S: ZFAT expression in B and T lymphocytes and identification of ZFAT-regulated genes. Genomics 91 : 451-457, 2008.
20. Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T and Shirasawa S: Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-Specific manner in colorectal cancer cells. Anticancer Res 31 : 2453-2459, 2011.
21. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H and Marra G: Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5: 1263-1275, 2007.
22. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P and Mesirov JP: GenePattern 2.0. Nat Genet 38: 500-501, 2006.
23. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD and Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 : 531-537, 1999.
24. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB and Rosen N: PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70: 6804-6814, 2010.
25. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C and Wheeler DL: Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30: 561-574, 2010.
26. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB and Solit DB: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70: 5901-5911, 2010.
27. Dehm S, Senger MA and Bonham K: SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 487 : 367-371, 2001.
28. Sena P, Roncucci L, Marzona L, Mariani F, Maffei S, Manenti A and De Pol A: Altered expression of apoptosis biomarkers in human colorectal microadenomas. Cancer Epidemiol Biomarkers Prev 19 : 351-357, 2010.
29. Rajagopalan H, Nowak MA, Vogelstein B and Lengauer C: The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3: 695-701, 2003.
30. Wang XW, Tseng A, Ellis NA, Spillare EA, Linke SP, Robles AI, Seker H, Yang Q, Hu P, Beresten S, Bemmels NA, Garfield S and Harris CC: Functional interaction of p53 and BLM DNA helicase in apoptosis. J Biol Chem 276: 32948-32955, 2001.
31. Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G and Offit K: BLM heterozygosity and the risk of colorectal cancer. Science 297: 2013, 2002.
32. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ and Qin J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14: 927-939, 2000.
33. Krupa R, Sliwinski T, Wisniewska-Jarosinska M, Chojnacki J, Wasylecka M, Dziki L, Morawiec J and Blasiak J: Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer - a case control study. Mol Biol Rep 38 : 2849-2854, 2011.
34. Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR and Kern SE: Gene-specific selection against experimental Fanconi anemia gene inactivation in human cancer. Cancer Biol Ther 6: 654-660, 2007.
35. Freie B, Li X, Ciccone SL, Nawa K, Cooper S, Vogelweid C, Schantz L, Haneline LS, Orazi A, Broxmeyer HE, Lee SH and Clapp DW: Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 102: 4146-4152, 2003.
36. Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G and Amariglio N: Co-inheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. Am J Hematol 78 : 203-206, 2005.
37. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M and D'Andrea AD: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7: 249-262, 2001.